Ovarian cancer as a genetic disease

Frontiers in Bioscience

Volumn 18, Issue 2, 2013, Pages 543-563

  Lech, Agnieszka ^a,b   Daneva, Teodora ^c   Pashova, Shina ^c   Gagov, Hristo ^d   Crayton, Robert ^e   Kukwa, Wojciech ^e   Czarnecka, Anna M ^a   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b UNIVERSITY OF WARSAW   (Poland)

^c Institute of Biology and Immunology of Reproduction   (Bulgaria)

^d UNIVERSITY OF SOFIA   (Bulgaria)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

BRCA1; BRCA2; Cancerogenesis; Ovarian cancer; PIK3CA; Review; Signaling pathway; TP53

Indexed keywords

CELL TRANSFORMATION; FEMALE; GENETICS; HUMAN; OVARY TUMOR; PHYSIOLOGY; PRECANCER; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, P53; HUMANS; OVARIAN NEOPLASMS; PRECANCEROUS CONDITIONS; PROGNOSIS; SIGNAL TRANSDUCTION;

MLCS; MLOWN;

EID: 84878772697     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4119     Document Type: Review

References (231)

1. A. J. Li, P. McAllister and B. Y. Karlan: Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutationassociated epithelial ovarian cancers. Gynecologic oncology, 116 (1), 105-8 (2010)
2. P. Tagliaferri, M. Ventura, F. Baudi, I. Cucinotto, M. Arbitrio, M. T. Di Martino and P. Tassone: BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality? Journal of ovarian research, 2, 14 (2009)
3. A. D. Forman and M. J. Hall: Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer. The breast journal, 15 Suppl 1, S56-62 (2009)
4. B. Drohan, E. M. Ozanne and K. S. Hughes: Electronic health records and the management of women at high risk of hereditary breast and ovarian cancer. The breast journal, 15 Suppl 1, S46-55 (2009)
5. S. R. Lakhani, S. Manek, F. Penault-Llorca, A. Flanagan, L. Arnout, S. Merrett, L. McGuffog, D. Steele, P. Devilee, J. G. Klijn, H. Meijers-Heijboer, P. Radice, S. Pilotti, H. Nevanlinna, R. Butzow, H. Sobol, J. Jacquemier, D. S. Lyonet, S. L. Neuhausen, B. Weber, T. Wagner, R. Winqvist, Y. J. Bignon, F. Monti, F. Schmitt, G. Lenoir, S. Seitz, U. Hamman, P. Pharoah, G. Lane, B. Ponder, D. T. Bishop and D. F. Easton: Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clinical cancer research : an official journal of the American Association for Cancer Research, 10 (7), 2473-81 (2004) (Pubitemid 38445709)
6. P. B. Mullan, J. E. Quinn and D. P. Harkin: The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene, 25 (43), 5854-63 (2006) (Pubitemid 44453441)
7. R. Scully, J. Chen, A. Plug, Y. Xiao, D. Weaver, J. Feunteun, T. Ashley and D. M. Livingston: Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell, 88 (2), 265-75 (1997) (Pubitemid 28015875)
8. C. Vo and M. E. Carney: Ovarian cancer hormonal and environmental risk effect. Obstetrics and gynecology clinics of North America, 34 (4), 687-700, viii (2007) (Pubitemid 350182430)
9. C. A. Bandera: Advances in the understanding of risk factors for ovarian cancer. The Journal of reproductive medicine, 50 (6), 399-406 (2005) (Pubitemid 40863956)
10. D. A. Bell: Origins and molecular pathology of ovarian cancer. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 18 Suppl 2, S19-32 (2005) (Pubitemid 40188615)
11. R. C. Bast, Jr., B. Hennessy and G. B. Mills: The biology of ovarian cancer: new opportunities for translation. Nature reviews. Cancer, 9 (6), 415-28 (2009)
12. F. Balkwill, R. C. Bast, J. Berek, G. Chenevix-Trench, M. Gore, T. Hamilton, I. Jacobs, G. Mills, R. Souhami, N. Urban, S. Orsulic and J. Smyth: Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. European journal of cancer, 39 (13), 1818-27 (2003) (Pubitemid 37311176)
13. B. A. Werness, P. Parvatiyar, S. J. Ramus, A. S. Whittemore, K. Garlinghouse-Jones, I. Oakley-Girvan, R. A. DiCioccio, J. Wiest, Y. Tsukada, B. A. Ponder and M. S. Piver: Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53. Journal of the National Cancer Institute, 92 (13), 1088-91 (2000) (Pubitemid 30616483)
14. J. L. Hilton, J. P. Geisler, J. A. Rathe, M. A. Hattermann- Zogg, B. DeYoung and R. E. Buller: Inactivation of BRCA1 and BRCA2 in ovarian cancer. Journal of the National Cancer Institute, 94 (18), 1396-406 (2002) (Pubitemid 35154144)
15. J. P. Geisler, M. A. Hatterman-Zogg, J. A. Rathe and R. E. Buller: Frequency of BRCA1 dysfunction in ovarian cancer. Journal of the National Cancer Institute, 94 (1), 61-7 (2002) (Pubitemid 34082844)
16. G. Singer, R. Oldt, 3rd, Y. Cohen, B. G. Wang, D. Sidransky, R. J. Kurman and M. Shih Ie: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. Journal of the National Cancer Institute, 95 (6), 484-6 (2003) (Pubitemid 36432423)
17. G. Singer, R. J. Kurman, H. W. Chang, S. K. Cho and M. Shih Ie: Diverse tumorigenic pathways in ovarian serous carcinoma. The American journal of pathology, 160 (4), 1223-8 (2002)
18. S. E. Russell and W. G. McCluggage: A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. The Journal of pathology, 203 (2), 617-9 (2004) (Pubitemid 38714096)
19. N. L. Sieben, P. Macropoulos, G. M. Roemen, S. M. Kolkman-Uljee, G. Jan Fleuren, R. Houmadi, T. Diss, B. Warren, M. Al Adnani, A. P. De Goeij, T. Krausz and A. M. Flanagan: In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. The Journal of pathology, 202 (3), 336-40 (2004) (Pubitemid 38325243)
20. M. L. Gemignani, A. C. Schlaerth, F. Bogomolniy, R. R. Barakat, O. Lin, R. Soslow, E. Venkatraman and J. Boyd: Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecologic oncology, 90 (2), 378-81 (2003) (Pubitemid 36952030)
21. A. P. Garrett, K. R. Lee, C. R. Colitti, M. G. Muto, R. S. Berkowitz and S. C. Mok: k-ras mutation may be an early event in mucinous ovarian tumorigenesis. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 20 (3), 244-51 (2001) (Pubitemid 32578110)
22. J. Palacios and C. Gamallo: Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer research, 58 (7), 1344-7 (1998)
23. C. Gamallo, J. Palacios, G. Moreno, J. Calvo de Mora, A. Suarez and A. Armas: beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. The American journal of pathology, 155 (2), 527-36 (1999) (Pubitemid 29370402)
24. N. Sato, H. Tsunoda, M. Nishida, Y. Morishita, Y. Takimoto, T. Kubo and M. Noguchi: Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer research, 60 (24), 7052-6 (2000)
25. T. Okuda, J. Otsuka, A. Sekizawa, H. Saito, R. Makino, M. Kushima, A. Farina, Y. Kuwano and T. Okai: p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecologic oncology, 88 (3), 318-25 (2003) (Pubitemid 36331984)
26. L. Havrilesky, M. Darcy, H. Hamdan, R. L. Priore, J. Leon, J. Bell and A. Berchuck: Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 (20), 3814-25 (2003) (Pubitemid 46606237)
27. B. L. King, M. L. Carcangiu, D. Carter, M. Kiechle, J. Pfisterer, A. Pfleiderer and B. M. Kacinski: Microsatellite instability in ovarian neoplasms. British journal of cancer, 72 (2), 376-82 (1995)
28. A. K. Sood, J. S. Skilling and R. E. Buller: Ovarian cancer genomic instability correlates with p53 frameshift mutations. Cancer research, 57 (6), 1047-9 (1997)
29. M. S. Chapman and I. M. Verma: Transcriptional activation by BRCA1. Nature, 382 (6593), 678-9 (1996) (Pubitemid 26282163)
30. A. N. Monteiro, A. August and H. Hanafusa: Evidence for a transcriptional activation function of BRCA1 Cterminal region. Proceedings of the National Academy of Sciences of the United States of America, 93 (24), 13595-9 (1996)
31. R. Scully, S. F. Anderson, D. M. Chao, W. Wei, L. Ye, R. A. Young, D. M. Livingston and J. D. Parvin: BRCA1 is a component of the RNA polymerase II holoenzyme. Proceedings of the National Academy of Sciences of the United States of America, 94 (11), 5605-10 (1997) (Pubitemid 27241816)
32. S. T. Marquis, J. V. Rajan, A. Wynshaw-Boris, J. Xu, G. Y. Yin, K. J. Abel, B. L. Weber and L. A. Chodosh: The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nature genetics, 11 (1), 17-26 (1995)
33. Y. Miki, J. Swensen, D. Shattuck-Eidens, P. A. Futreal, K. Harshman, S. Tavtigian, Q. Liu, C. Cochran, L. M. Bennett, W. Ding and et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266 (5182), 66-71 (1994) (Pubitemid 24345325)
34. J. Simard, P. Tonin, F. Durocher, K. Morgan, J. Rommens, S. Gingras, C. Samson, J. F. Leblanc, C. Belanger, F. Dion and et al.: Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nature genetics, 8 (4), 392-8 (1994) (Pubitemid 24375607)
35. L. S. Friedman, E. A. Ostermeyer, C. I. Szabo, P. Dowd, E. D. Lynch, S. E. Rowell and M. C. King: Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nature genetics, 8 (4), 399-404 (1994) (Pubitemid 24375608)
36. J. Chen, D. P. Silver, D. Walpita, S. B. Cantor, A. F. Gazdar, G. Tomlinson, F. J. Couch, B. L. Weber, T. Ashley, D. M. Livingston and R. Scully: Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Molecular cell, 2 (3), 317-28 (1998) (Pubitemid 128379272)
37. D. C. Daniel: Highlight: BRCA1 and BRCA2 proteins in breast cancer. Microscopy research and technique, 59 (1), 68-83 (2002)
38. L. Pellegrini, D. S. Yu, T. Lo, S. Anand, M. Lee, T. L. Blundell and A. R. Venkitaraman: Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature, 420 (6913), 287-93 (2002) (Pubitemid 35398178)
39. H. Ruffner, C. A. Joazeiro, D. Hemmati, T. Hunter and I. M. Verma: Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proceedings of the National Academy of Sciences of the United States of America, 98 (9), 5134-9 (2001)
40. T. F. Lane, C. Deng, A. Elson, M. S. Lyu, C. A. Kozak and P. Leder: Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes & development, 9 (21), 2712-22 (1995)
41. J. J. Gorski, R. D. Kennedy, A. M. Hosey and D. P. Harkin: The complex relationship between BRCA1 and ERalpha in hereditary breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 15 (5), 1514-8 (2009)
42. S. Fan, Y. X. Ma, C. Wang, R. Q. Yuan, Q. Meng, J. A. Wang, M. Erdos, I. D. Goldberg, P. Webb, P. J. Kushner, R. G. Pestell and E. M. Rosen: p300 Modulates the BRCA1 inhibition of estrogen receptor activity. Cancer research, 62 (1), 141-51 (2002) (Pubitemid 34073998)
43. S. R. Lakhani, M. J. Van De Vijver, J. Jacquemier, T. J. Anderson, P. P. Osin, L. McGuffog and D. F. Easton: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 (9), 2310-8 (2002)
44. S. R. Lakhani, J. S. Reis-Filho, L. Fulford, F. Penault- Llorca, M. van der Vijver, S. Parry, T. Bishop, J. Benitez, C. Rivas, Y. J. Bignon, J. Chang-Claude, U. Hamann, C. J. Cornelisse, P. Devilee, M. W. Beckmann, C. Nestle- Kramling, P. A. Daly, N. Haites, J. Varley, F. Lalloo, G. Evans, C. Maugard, H. Meijers-Heijboer, J. G. Klijn, E. Olah, B. A. Gusterson, S. Pilotti, P. Radice, S. Scherneck, H. Sobol, J. Jacquemier, T. Wagner, J. Peto, M. R. Stratton, L. McGuffog and D. F. Easton: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clinical cancer research : an official journal of the American Association for Cancer Research, 11 (14), 5175-80 (2005) (Pubitemid 41003703)
45. W. D. Foulkes, I. M. Stefansson, P. O. Chappuis, L. R. Begin, J. R. Goffin, N. Wong, M. Trudel and L. A. Akslen: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. Journal of the National Cancer Institute, 95 (19), 1482-5 (2003)
46. O. T. Johannsson, I. Idvall, C. Anderson, A. Borg, R. B. Barkardottir, V. Egilsson and H. Olsson: Tumour biological features of BRCA1-induced breast and ovarian cancer. European journal of cancer, 33 (3), 362-71 (1997)
47. L. C. Verhoog, C. T. Brekelmans, C. Seynaeve, L. M. van den Bosch, G. Dahmen, A. N. van Geel, M. M. Tilanus-Linthorst, C. C. Bartels, A. Wagner, A. van den Ouweland, P. Devilee, E. J. Meijers-Heijboer and J. G. Klijn: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet, 351 (9099), 316-21 (1998) (Pubitemid 28052696)
48. E. J. Folkerd, L. A. Martin, A. Kendall and M. Dowsett: The relationship between factors affecting endogenous oestradiol levels in postmenopausal women and breast cancer. The Journal of steroid biochemistry and molecular biology, 102 (1-5), 250-5 (2006) (Pubitemid 44750647)
49. R. Kaaks, S. Rinaldi, T. J. Key, F. Berrino, P. H. Peeters, C. Biessy, L. Dossus, A. Lukanova, S. Bingham, K. T. Khaw, N. E. Allen, H. B. Bueno-de-Mesquita, C. H. van Gils, D. Grobbee, H. Boeing, P. H. Lahmann, G. Nagel, J. Chang-Claude, F. Clavel-Chapelon, A. Fournier, A. Thiebaut, C. A. Gonzalez, J. R. Quiros, M. J. Tormo, E. Ardanaz, P. Amiano, V. Krogh, D. Palli, S. Panico, R. Tumino, P. Vineis, A. Trichopoulou, V. Kalapothaki, D. Trichopoulos, P. Ferrari, T. Norat, R. Saracci and E. Riboli: Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocrinerelated cancer, 12 (4), 1071-82 (2005) (Pubitemid 41815798)
50. S. V. Tavtigian, J. Simard, J. Rommens, F. Couch, D. Shattuck-Eidens, S. Neuhausen, S. Merajver, S. Thorlacius, K. Offit, D. Stoppa-Lyonnet, C. Belanger, R. Bell, S. Berry, R. Bogden, Q. Chen, T. Davis, M. Dumont, C. Frye, T. Hattier, S. Jammulapati, T. Janecki, P. Jiang, R. Kehrer, J. F. Leblanc, J. T. Mitchell, J. McArthur-Morrison, K. Nguyen, Y. Peng, C. Samson, M. Schroeder, S. C. Snyder, L. Steele, M. Stringfellow, C. Stroup, B. Swedlund, J. Swense, D. Teng, A. Thomas, T. Tran, M. Tranchant, J. Weaver-Feldhaus, A. K. Wong, H. Shizuya, J. E. Eyfjord, L. Cannon- Albright, F. Labrie, M. H. Skolnick, B. Weber, A. Kamb and D. E. Goldgar: The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nature genetics, 12 (3), 333-7 (1996) (Pubitemid 26080098)
51. J. Milner, B. Ponder, L. Hughes-Davies, M. Seltmann and T. Kouzarides: Transcriptional activation functions in BRCA2. Nature, 386 (6627), 772-3 (1997)
52. S. A. Gayther, J. Mangion, P. Russell, S. Seal, R. Barfoot, B. A. Ponder, M. R. Stratton and D. Easton: Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nature genetics, 15 (1), 103-5 (1997) (Pubitemid 27014960)
53. H. Takahashi, H. C. Chiu, C. A. Bandera, K. Behbakht, P. C. Liu, F. J. Couch, B. L. Weber, V. A. LiVolsi, M. Furusato, B. A. Rebane, A. Cardonick, I. Benjamin, M. A. Morgan, S. A. King, J. J. Mikuta, S. C. Rubin and J. Boyd: Mutations of the BRCA2 gene in ovarian carcinomas. Cancer research, 56 (12), 2738-41 (1996) (Pubitemid 26175729)
54. G. Matlashewski, P. Lamb, D. Pim, J. Peacock, L. Crawford and S. Benchimol: Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. The EMBO journal, 3 (13), 3257-62 (1984)
55. S. E. Kern, K. W. Kinzler, A. Bruskin, D. Jarosz, P. Friedman, C. Prives and B. Vogelstein: Identification of p53 as a sequence-specific DNA-binding protein. Science, 252 (5013), 1708-11 (1991) (Pubitemid 21917093)
56. M. Isobe, B. S. Emanuel, D. Givol, M. Oren and C. M. Croce: Localization of gene for human p53 tumour antigen to band 17p13. Nature, 320 (6057), 84-5 (1986) (Pubitemid 16105254)
57. D. P. Lane: Cancer. p53, guardian of the genome. Nature, 358 (6381), 15-6 (1992)
58. K. M. Ryan, A. C. Phillips and K. H. Vousden: Regulation and function of the p53 tumor suppressor protein. Current opinion in cell biology, 13 (3), 332-7 (2001) (Pubitemid 32429498)
59. M. S. Greenblatt, W. P. Bennett, M. Hollstein and C. C. Harris: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer research, 54 (18), 4855-78 (1994) (Pubitemid 24289415)
60. Y. Wang, P. Kringen, G. B. Kristensen, R. Holm, M. M. Baekelandt, M. Olivier, H. Skomedal, P. Hainaut, C. G. Trope, V. M. Abeler, J. M. Nesland, A. L. Borresen-Dale and A. Helland: Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Human mutation, 24 (1), 21-34 (2004) (Pubitemid 38859221)
61. L. M. Kmet, L. S. Cook and A. M. Magliocco: A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer, 97 (2), 389-404 (2003) (Pubitemid 36133806)
62. A. Berchuck, M. F. Kohler, M. P. Hopkins, P. A. Humphrey, S. J. Robboy, G. C. Rodriguez, J. T. Soper, D. L. Clarke-Pearson and R. C. Bast: Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecologic oncology, 52 (2), 232-6 (1994) (Pubitemid 24064376)
63. M. Q. Bernardini, T. Baba, P. S. Lee, J. C. Barnett, G. P. Sfakianos, A. A. Secord, S. K. Murphy, E. Iversen, J. R.Marks and A. Berchuck: Expression signatures of TP53 mutations in serous ovarian cancers. BMC cancer, 10, 237 (2010)
64. K. W. Kinzler and B. Vogelstein: Cancer therapy meets p53. The New England journal of medicine, 331 (1), 49-50 (1994) (Pubitemid 24195604)
65. S. W. Beenken, G. Karsenty, L. Raycroft and G. Lozano: An intron binding protein is required for transformation ability of p53. Nucleic acids research, 19 (17), 4747-52 (1991) (Pubitemid 21912859)
66. G. J. Matlashewski, S. Tuck, D. Pim, P. Lamb, J. Schneider and L. V. Crawford: Primary structure polymorphism at amino acid residue 72 of human p53. Molecular and cellular biology, 7 (2), 961-3 (1987) (Pubitemid 17004567)
67. M. Thomas, A. Kalita, S. Labrecque, D. Pim, L. Banks and G. Matlashewski: Two polymorphic variants of wildtype p53 differ biochemically and biologically. Molecular and cellular biology, 19 (2), 1092-100 (1999) (Pubitemid 29046852)
68. K. K. Walker and A. J. Levine: Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proceedings of the National Academy of Sciences of the United States of America, 93 (26), 15335-40 (1996)
69. E. Malisic, R. Jankovic, D. Slavkovic, M. Milovic- Kovacevic and S. Radulovic: p53 gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 15 (1), 101-6 (2010)
70. A. Langerod, I. R. Bukholm, A. Bregard, P. E. Lonning, T. I. Andersen, T. O. Rognum, G. I. Meling, R. A. Lothe and A. L. Borresen-Dale: The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 11 (12), 1684-8 (2002)
71. P. Dumont, J. I. Leu, A. C. Della Pietra, 3rd, D. L. George and M. Murphy: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature genetics, 33 (3), 357-65 (2003) (Pubitemid 36278852)
72. G. Hofstetter, A. Berger, H. Fiegl, N. Slade, A. Zoric, B. Holzer, E. Schuster, V. J. Mobus, D. Reimer, G. Daxenbichler, C. Marth, A. G. Zeimet, N. Concin and R. Zeillinger: Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene, 29 (13), 1997-2004 (2010)
73. T. Ouchi, A. N. Monteiro, A. August, S. A. Aaronson and H. Hanafusa: BRCA1 regulates p53-dependent gene expression. Proceedings of the National Academy of Sciences of the United States of America, 95 (5), 2302-6 (1998)
74. H. Zhang, K. Somasundaram, Y. Peng, H. Tian, D. Bi, B. L. Weber and W. S. El-Deiry: BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene, 16 (13), 1713-21 (1998) (Pubitemid 28175052)
75. K. W. Kinzler and B. Vogelstein: Cancer-susceptibility genes. Gatekeepers and caretakers. Nature, 386 (6627), 761, 763 (1997)
76. J. J. Harvey: An Unidentified Virus Which Causes the Rapid Production of Tumours in Mice. Nature, 204, 1104-5 (1964)
77. W. H. Kirsten, V. Schauf and J. McCoy: Properties of a murine sarcoma virus. Bibliotheca haematologica (36), 246-9 (1970)
78. G. M. Cooper: Cellular transforming genes. Science, 217 (4562), 801-6 (1982) (Pubitemid 12042904)
79. E. Santos, S. R. Tronick, S. A. Aaronson, S. Pulciani and M. Barbacid: T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature, 298 (5872), 343-7 (1982) (Pubitemid 12044286)
80. L. F. Parada, C. J. Tabin, C. Shih and R. A. Weinberg: Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature, 297 (5866), 474-8 (1982) (Pubitemid 12007526)
81. M. Barbacid: ras genes. Annual review of biochemistry, 56, 779-827 (1987)
82. N. C. Popescu, S. C. Amsbaugh, J. A. DiPaolo, S. R. Tronick, S. A. Aaronson and D. C. Swan: Chromosomal localization of three human ras genes by in situ molecular hybridization. Somatic cell and molecular genetics, 11 (2), 149-55 (1985) (Pubitemid 15149288)
83. D. S. Goodsell: The molecular perspective: the ras oncogene. The oncologist, 4 (3), 263-4 (1999) (Pubitemid 29297488)
84. J. L. Bos: ras oncogenes in human cancer: a review. Cancer research, 49 (17), 4682-9 (1989)
85. D. Mayr, A. Hirschmann, U. Lohrs and J. Diebold: KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecologic oncology, 103 (3), 883-7 (2006) (Pubitemid 44821309)
86. R. F. Caduff, S. M. Svoboda-Newman, A. W. Ferguson, C. M. Johnston and T. S. Frank: Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. The American journal of surgical pathology, 23 (3), 323-8 (1999) (Pubitemid 29117569)
87. V. Auner, G. Kriegshauser, D. Tong, R. Horvat, A. Reinthaller, A. Mustea and R. Zeillinger: KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC cancer, 9, 111 (2009)
88. G. Fabjani, G. Kriegshaeuser, A. Schuetz, L. Prix and R. Zeillinger: Biochip for K-ras mutation screening in ovarian cancer. Clinical chemistry, 51 (4), 784-7 (2005) doi:10.1373/clinchem.2004.041194 (Pubitemid 40463933)
89. S. C. Mok, D. A. Bell, R. C. Knapp, P. M. Fishbaugh, W. R. Welch, M. G. Muto, R. S. Berkowitz and S. W. Tsao: Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer research, 53 (7), 1489-92 (1993) (Pubitemid 23113216)
90. T. Enomoto, C. M. Weghorst, M. Inoue, O. Tanizawa and J. M. Rice: K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. The American journal of pathology, 139 (4), 777-85 (1991)
91. M. G. Teneriello, M. Ebina, R. I. Linnoila, M. Henry, J. D. Nash, R. C. Park and M. J. Birrer: p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer research, 53 (13), 3103-8 (1993)
92. O. Kranenburg: The KRAS oncogene: past, present, and future. Biochimica et biophysica acta, 1756 (2), 81-2 (2005) (Pubitemid 41773135)
93. P. Rodriguez-Viciana, P. H. Warne, B. Vanhaesebroeck, M. D. Waterfield and J. Downward: Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. The EMBO journal, 15 (10), 2442-51 (1996) (Pubitemid 26151184)
94. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, S. Szabo, H. Yan, A. Gazdar, S. M. Powell, G. J. Riggins, J. K. Willson, S. Markowitz, K. W. Kinzler, B. Vogelstein and V. E. Velculescu: High frequency of mutations of the PIK3CA gene in human cancers. Science, 304 (5670), 554 (2004) (Pubitemid 38541907)
95. L. Shayesteh, Y. Lu, W. L. Kuo, R. Baldocchi, T. Godfrey, C. Collins, D. Pinkel, B. Powell, G. B. Mills and J. W. Gray: PIK3CA is implicated as an oncogene in ovarian cancer. Nature genetics, 21 (1), 99-102 (1999) (Pubitemid 29036292)
96. J. Woenckhaus, K. Steger, K. Sturm, K. Munstedt, F. E. Franke and I. Fenic: Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer. Virchows Archiv : an international journal of pathology, 450 (4), 387-95 (2007) (Pubitemid 46466383)
97. I. K. Kolasa, A. Rembiszewska, A. Felisiak, I. Ziolkowska-Seta, M. Murawska, J. Moes, A. Timorek, A. Dansonka-Mieszkowska and J. Kupryjanczyk: PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer biology & therapy, 8 (1), 21-6 (2009)
98. S. Liang, N. Yang, Y. Pan, S. Deng, X. Lin, X. Yang, D. Katsaros, K. F. Roby, T. C. Hamilton, D. C. Connolly, G. Coukos and L. Zhang: Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation. PloS one, 4 (1), e4295 (2009)
99. X. Zhang, H. X. Deng, X. Zhao, D. Su, X. C. Chen, L. J. Chen, Y. Q. Wei, Q. Zhong, Z. Y. Li, X. He and T. Yi: RNA interference-mediated silencing of the phosphatidylinositol 3-kinase catalytic subunit attenuates growth of human ovarian cancer cells in vitroand in vivo. Oncology, 77 (1), 22-32 (2009)
100. L. Zhang, N. Yang, D. Katsaros, W. Huang, J. W. Park, S. Fracchioli, C. Vezzani, I. A. Rigault de la Longrais, W. Yao, S. C. Rubin and G. Coukos: The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer research, 63 (14), 4225-31 (2003) (Pubitemid 36917950)
101. R. Marone, V. Cmiljanovic, B. Giese and M. P. Wymann: Targeting phosphoinositide 3-kinase: moving towards therapy. Biochimica et biophysica acta, 1784 (1), 159-85 (2008)
102. L. Zhang, N. Yang, S. Liang, A. Barchetti, C. Vezzani, J. Huang, A. O'Brien-Jenkins, S. C. Rubin and G. Coukos: RNA interference: a potential strategy for isoformspecific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer. Cancer biology & therapy, 3 (12), 1283-9 (2004)
103. A. Astanehe, D. Arenillas, W. W. Wasserman, P. C. Leung, S. E. Dunn, B. R. Davies, G. B. Mills and N. Auersperg: Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. Journal of cell science, 121 (Pt 5), 664-74 (2008) (Pubitemid 351524165)
104. C. Kraus, T. Liehr, J. Hulsken, J. Behrens, W. Birchmeier, K. H. Grzeschik and W. G. Ballhausen: Localization of the human beta-catenin gene (CTNNB1) to 3p21: a region implicated in tumor development. Genomics, 23 (1), 272-4 (1994)
105. R. B. Hazan and L. Norton: The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. The Journal of biological chemistry, 273 (15), 9078-84 (1998) (Pubitemid 28176196)
106. K. Takahashi, K. Suzuki and Y. Tsukatani: Induction of tyrosine phosphorylation and association of beta-catenin with EGF receptor upon tryptic digestion of quiescent cells at confluence. Oncogene, 15 (1), 71-8 (1997) (Pubitemid 27348098)
107. J. A. Schroeder, M. C. Adriance, E. J. McConnell, M. C. Thompson, B. Pockaj and S. J. Gendler: ErbB-betacatenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)- Wnt-1 and MMTV-c-Neu transgenic carcinomas. The Journal of biological chemistry, 277 (25), 22692-8 (2002)
108. P. Bonvini, W. G. An, A. Rosolen, P. Nguyen, J. Trepel, A. Garcia de Herreros, M. Dunach and L. M. Neckers: Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription. Cancer research, 61 (4), 1671-7 (2001)
109. Y. Kanai, A. Ochiai, T. Shibata, T. Oyama, S. Ushijima, S. Akimoto and S. Hirohashi: c-erbB-2 gene product directly associates with beta-catenin and plakoglobin. Biochemical and biophysical research communications, 208 (3), 1067-72 (1995)
110. A. Bauer, O. Huber and R. Kemler: Pontin52, an interaction partner of beta-catenin, binds to the TATA box binding protein. Proceedings of the National Academy of Sciences of the United States of America, 95 (25), 14787- 92 (1998)
111. J. Lilien and J. Balsamo: The regulation of cadherinmediated adhesion by tyrosine phosphorylation/dephosphorylation of beta-catenin. Current opinion in cell biology, 17 (5), 459-65 (2005) (Pubitemid 41267159)
112. M. D. Castellone, H. Teramoto, B. O. Williams, K. M. Druey and J. S. Gutkind: Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science, 310 (5753), 1504-10 (2005) (Pubitemid 41746348)
113. S. Hino, C. Tanji, K. I. Nakayama and A. Kikuchi: Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Molecular and cellular biology, 25 (20), 9063-72 (2005) (Pubitemid 41429094)
114. X. Wang, E. L. Goode, Z. S. Fredericksen, R. A. Vierkant, V. S. Pankratz, W. Liu-Mares, D. N. Rider, C. M. Vachon, J. R. Cerhan, J. E. Olson and F. J. Couch: Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 17 (8), 2101-8 (2008)
115. G. Saldanha, V. Ghura, L. Potter and A. Fletcher: Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation. The British journal of dermatology, 151 (1), 157-64 (2004) (Pubitemid 39061293)
116. S. Sagae, K. Kobayashi, Y. Nishioka, M. Sugimura, S. Ishioka, M. Nagata, K. Terasawa, T. Tokino and R. Kudo: Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas. Japanese journal of cancer research : Gann, 90 (5), 510-5 (1999) (Pubitemid 29267704)
117. K. Wright, P. Wilson, S. Morland, I. Campbell, M. Walsh, T. Hurst, B. Ward, M. Cummings and G. Chenevix- Trench: beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. International journal of cancer. Journal international du cancer, 82 (5), 625-9 (1999) (Pubitemid 29356957)
118. E. Oliva, D. Sarrio, E. F. Brachtel, C. Sanchez- Estevez, R. A. Soslow, G. Moreno-Bueno and J. Palacios: High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary. The Journal of pathology, 208 (5), 708-13 (2006)
119. J. Fujimoto, S. Ichigo, R. Hirose, H. Sakaguchi and T. Tamaya: Expression of E-cadherin and alpha- and betacatenin mRNAs in ovarian cancers. Cancer letters, 115 (2), 207-12 (1997) (Pubitemid 27196607)
120. B. R. Davies, S. D. Worsley and B. A. Ponder: Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology, 32 (1), 69-80 (1998)
121. C. Faleiro-Rodrigues, I. M. Macedo-Pinto, S. S. Maia, R. H. Vieira and C. S. Lopes: Biological relevance of Ecadherin- catenin complex proteins in primary epithelial ovarian tumours. Gynecologic and obstetric investigation, 60 (2), 75-83 (2005) (Pubitemid 41159846)
122. C. Faleiro-Rodrigues, I. Macedo-Pinto, D. Pereira and C. S. Lopes: Loss of beta-catenin is associated with poor survival in ovarian carcinomas. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 23 (4), 337-46 (2004) (Pubitemid 39299022)
123. D. G. Rosen, Z. Zhang, B. Chang, X. Wang, E. Lin and J. Liu: Low membranous expression of beta-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 23 (1), 113-22 (2010)
124. M. Saito, A. Okamoto, T. Kohno, S. Takakura, H. Shinozaki, S. Isonishi, T. Yasuhara, T. Yoshimura, Y. Ohtake, K. Ochiai, J. Yokota and T. Tanaka: Allelic imbalance and mutations of the PTEN gene in ovarian cancer. International journal of cancer. Journal international du cancer, 85 (2), 160-5 (2000) (Pubitemid 30023061)
125. Y. Takei, Y. Saga, H. Mizukami, T. Takayama, M. Ohwada, K. Ozawa and M. Suzuki: Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice. Molecular cancer therapeutics, 7 (3), 704-11 (2008) (Pubitemid 351482153)
126. Y. Saga, H. Mizukami, Y. Takei, K. Ozawa and M. Suzuki: Suppression of cell migration in ovarian cancer cells mediated by PTEN overexpression. International journal of oncology, 23 (4), 1109-13 (2003)
127. A. D. Santin, S. Bellone, J. J. Roman, J. K. McKenney and S. Pecorelli: Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 102 (2), 128-31 (2008)
128. I. G. Campbell, T. A. Jones, W. D. Foulkes and J. Trowsdale: Folate-binding protein is a marker for ovarian cancer. Cancer research, 51 (19), 5329-38 (1991)
129. M. D. Salazar and M. Ratnam: The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer metastasis reviews, 26 (1), 141-52 (2007) (Pubitemid 46452188)
130. L. E. Kelemen: The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? International journal of cancer. Journal international du cancer, 119 (2), 243-50 (2006)
131. G. Toffoli, C. Cernigoi, A. Russo, A. Gallo, M. Bagnoli and M. Boiocchi: Overexpression of folate binding protein in ovarian cancers. International journal of cancer. Journal international du cancer, 74 (2), 193-8 (1997) (Pubitemid 27234510)
132. A. C. Antony: The biological chemistry of folate receptors. Blood, 79 (11), 2807-20 (1992)
133. J. F. Ross, P. K. Chaudhuri and M. Ratnam: Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer, 73 (9), 2432- 43 (1994) (Pubitemid 24129130)
134. R. Veggian, S. Fasolato, S. Menard, D. Minucci, P. Pizzetti, M. Regazzoni, E. Tagliabue and M. I. Colnaghi: Immunohistochemical reactivity of a monoclonal antibody prepared against human ovarian carcinoma on normal and pathological female genital tissues. Tumori, 75 (5), 510-3 (1989) (Pubitemid 20064239)
135. Y. Yuan, D. A. Nymoen, H. P. Dong, O. Bjorang, M. Shih Ie, P. S. Low, C. G. Trope and B. Davidson: Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Human pathology, 40 (10), 1453-60 (2009)
136. A. Schmider-Ross, O. Pirsig, E. Gottschalk, C. Denkert, W. Lichtenegger and A. Reles: Cyclin-dependent kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer. Journal of cancer research and clinical oncology, 132 (3), 163- 70 (2006) (Pubitemid 43015777)
137. R. I. Yarden, E. Friedman, S. Metsuyanim, T. Olender, E. Ben-Asher and M. Z. Papa: MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast cancer research and treatment, 111 (3), 497-504 (2008)
138. D. Krekac, K. Brozkova, D. Knoflickova, R. Hrstka, P. Muller, R. Nenutil and B. Vojtesek: MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk. Oncology, 74 (1-2), 84-7 (2008) (Pubitemid 351915014)
139. F. Terauchi, A. Okamoto, T. Nagashima, Y. Kobayashi, T. Moritake, Y. Yamamoto, S. Takakura, S. Iwaki and H. Ogura: Clinical significance of p21 (WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary. Oncology reports, 14 (2), 363-8 (2005)
140. H. Lincet, L. Poulain, J. S. Remy, E. Deslandes, F. Duigou, P. Gauduchon and C. Staedel: The p21 (cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer letters, 161 (1), 17-26 (2000)
141. A. Schmider, C. Gee, W. Friedmann, J. J. Lukas, M. F. Press, W. Lichtenegger and A. Reles: p21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma. Gynecologic oncology, 77 (2), 237-42 (2000) (Pubitemid 30317142)
142. B. A. Werness, A. N. Freedman, M. S. Piver, M. Romero-Gutierrez and E. Petrow: Prognostic significance of p53 and p21 (waf1/cip1) immunoreactivity in epithelial cancers of the ovary. Gynecologic oncology, 75 (3), 413-8 (1999)
143. M. J. Costa, C. L. Hansen, J. E. Walls and S. A. Scudder: Immunohistochemical markers of cell cycle control applied to ovarian and primary peritoneal surface epithelial neoplasms: p21 (WAF1/CIP1) predicts survival and good response to platinin-based chemotherapy. Human pathology, 30 (6), 640-7 (1999) (Pubitemid 29266722)
144. M. Saegusa, B. D. Machida and I. Okayasu: Possible associations among expression of p14 (ARF), p16 (INK4a), p21 (WAF1/CIP1), p27 (KIP1), and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas. Cancer, 92 (5), 1177-89 (2001) (Pubitemid 32861667)
145. L. Sui, Y. Dong, M. Ohno, K. Sugimoto, Y. Tai, T. Hando and M. Tokuda: Implication of malignancy and prognosis of p27 (kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecologic oncology, 83 (1), 56-63 (2001) (Pubitemid 32959879)
146. J. Plisiecka-Halasa, G. Karpinska, T. Szymanska, I. Ziolkowska, R. Madry, A. Timorek, J. Debniak, M. Ulanska, M. Jedryka, A. Chudecka-Glaz, M. Klimek, A. Rembiszewska, E. Kraszewska, B. Dybowski, J. Markowska, J. Emerich, A. Pluzanska, M. Goluda, I. Rzepka-Gorska, K. Urbanski, J. Zielinski, J. Stelmachow, M. Chrabowska and J. Kupryjanczyk: P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinumbased regimens. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 14 (7), 1078-85 (2003) (Pubitemid 36950172)
147. S. Vuocolo, D. R. Soprano and K. J. Soprano: p27/Kip1 mediates retinoic acid-induced suppression of ovarian carcinoma cell growth. Journal of cellular physiology, 199 (2), 237-43 (2004) (Pubitemid 38436750)
148. A. Bali, P. M. O'Brien, L. S. Edwards, R. L. Sutherland, N. F. Hacker and S. M. Henshall: Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 10 (15), 5168-77 (2004) (Pubitemid 39099792)
149. D. G. Rosen, G. Yang, K. Q. Cai, R. C. Bast, Jr., D. M. Gershenson, E. G. Silva and J. Liu: Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 11 (2 Pt 1), 632-7 (2005) (Pubitemid 40116889)
150. B. Davidson, B. Risberg, A. Berner, J. M. Nesland, C. G. Trope, G. B. Kristensen, M. Bryne, M. Goscinski, G. van de Putte and V. A. Florenes: Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications. Gynecologic oncology, 83 (2), 249-56 (2001) (Pubitemid 33033061)
151. J. A. Hurteau, B. M. Allison, S. A. Brutkiewicz, M. G. Goebl, D. K. Heilman, R. M. Bigsby and M. A. Harrington: Expression and subcellular localization of the cyclindependent kinase inhibitor p27 (Kip1) in epithelial ovarian cancer. Gynecologic oncology, 83 (2), 292-8 (2001) (Pubitemid 33033069)
152. L. Sui, Y. Dong, M. Ohno, Y. Watanabe, K. Sugimoto, Y. Tai and M. Tokuda: Jab1 expression is associated with inverse expression of p27 (kip1) and poor prognosis in epithelial ovarian tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 7 (12), 4130-5 (2001)
153. K. Milde-Langosch, M. Hagen, A. M. Bamberger and T. Loning: Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2, in ovarian cancer. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 22 (2), 168-74 (2003) (Pubitemid 36348791)
154. J. Q. Cheng, A. K. Godwin, A. Bellacosa, T. Taguchi, T. F. Franke, T. C. Hamilton, P. N. Tsichlis and J. R. Testa: AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 89 (19), 9267-71 (1992)
155. A. Bellacosa, D. de Feo, A. K. Godwin, D. W. Bell, J. Q. Cheng, D. A. Altomare, M. Wan, L. Dubeau, G. Scambia, V. Masciullo, G. Ferrandina, P. Benedetti Panici, S. Mancuso, G. Neri and J. R. Testa: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. International journal of cancer. Journal international du cancer, 64 (4), 280-5 (1995)
156. A. X. Liu, J. R. Testa, T. C. Hamilton, R. Jove, S. V. Nicosia and J. Q. Cheng: AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3- kinase in human ovarian epithelial cancer cells. Cancer research, 58 (14), 2973-7 (1998)
157. Z. Q. Yuan, M. Sun, R. I. Feldman, G. Wang, X. Ma, C. Jiang, D. Coppola, S. V. Nicosia and J. Q. Cheng: Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene, 19 (19), 2324-30 (2000) (Pubitemid 30307208)
158. K. Nakayama, N. Nakayama, R. J. Kurman, L. Cope, G. Pohl, Y. Samuels, V. E. Velculescu, T. L. Wang and M. Shih Ie: Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer biology & therapy, 5 (7), 779-85 (2006) (Pubitemid 44775134)
159. I. G. Campbell, S. E. Russell, D. Y. Choong, K. G. Montgomery, M. L. Ciavarella, C. S. Hooi, B. E. Cristiano, R. B. Pearson and W. A. Phillips: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer research, 64 (21), 7678-81 (2004) (Pubitemid 39446895)
160. Y. Wang, A. Helland, R. Holm, G. B. Kristensen and A. L. Borresen-Dale: PIK3CA mutations in advanced ovarian carcinomas. Human mutation, 25 (3), 322 (2005)
161. C. I. Muller, C. W. Miller, W. K. Hofmann, M. E. Gross, C. S. Walsh, N. Kawamata, Q. T. Luong and H. P. Koeffler: Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leukemia research, 31 (1), 27-32 (2007) (Pubitemid 44709746)
162. J. Abubaker, P. Bavi, W. Al-Haqawi, Z. Jehan, A. Munkarah, S. Uddin and K. S. Al-Kuraya: PIK3CA alterations in Middle Eastern ovarian cancers. Molecular cancer, 8, 51 (2009)
163. H. J. Tang, X. Jin, S. Wang, D. Yang, Y. Cao, J. Chen, D. R. Gossett and J. Lin: A small molecule compound inhibits AKT pathway in ovarian cancer cell lines. Gynecologic oncology, 100 (2), 308-17 (2006) (Pubitemid 43078483)
164. D. Kim, M. Sun, L. He, Q. H. Zhou, J. Chen, X. M. Sun, G. Bepler, S. M. Sebti and J. Q. Cheng: A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. The Journal of biological chemistry, 285 (11), 8383-94 (2010)
165. A. Noske, A. Kaszubiak, W. Weichert, C. Sers, S. Niesporek, I. Koch, B. Schaefer, J. Sehouli, M. Dietel, H. Lage and C. Denkert: Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer. Cancer letters, 246 (1-2), 190-200 (2007) (Pubitemid 44959391)
166. D. Weng, X. Song, H. Xing, X. Ma, X. Xia, Y. Weng, J. Zhou, G. Xu, L. Meng, T. Zhu, S. Wang and D. Ma: Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. Cancer letters, 273 (2), 257-65 (2009)
167. R. B. Gaynor, C. Muchardt, Y. R. Xia, I. Klisak, T. Mohandas, R. S. Sparkes and A. J. Lusis: Localization of the gene for the DNA-binding protein AP-2 to human chromosome 6p22.3-pter. Genomics, 10 (4), 1100-2 (1991)
168. M. S. Gee, C. J. Sarkisian and W. S. el-Deiry: Identification of a novel AP-2 consensus DNA binding site. Biochemical and biophysical research communications, 243 (1), 307-16 (1998) (Pubitemid 28414233)
169. N. Mohibullah, A. Donner, J. A. Ippolito and T. Williams: SELEX and missing phosphate contact analyses reveal flexibility within the AP-2 (alpha) protein: DNA binding complex. Nucleic acids research, 27 (13), 2760-9 (1999)
170. L. A. McPherson, A. V. Loktev and R. J. Weigel: Tumor suppressor activity of AP2alpha mediated through a direct interaction with p53. The Journal of biological chemistry, 277 (47), 45028-33 (2002)
171. M. A. Anttila, J. K. Kellokoski, K. I. Moisio, P. J. Mitchell, S. Saarikoski, K. Syrjanen and V. M. Kosma: Expression of transcription factor AP-2alpha predicts survival in epithelial ovarian cancer. British journal of cancer, 82 (12), 1974-83 (2000) (Pubitemid 30326459)
172. S. Sumigama, T. Ito, H. Kajiyama, K. Shibata, K. Tamakoshi, F. Kikkawa, T. Williams, M. A. Tainsky, S. Nomura and S. Mizutani: Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by overexpression of AP-2alpha. Oncogene, 23 (32), 5496- 504 (2004) (Pubitemid 39044060)
173. E. Odegaard, A. C. Staff, J. Kaern, V. A. Florenes, J. Kopolovic, C. G. Trope, V. M. Abeler, R. Reich and B. Davidson: The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. Gynecologic oncology, 100 (3), 462-8 (2006) (Pubitemid 43246860)
174. J. Salonen, A. Leminen, U. H. Stenman, R. Butzow, M. Heikinheimo and O. Heikinheimo: Tissue AP-2gamma and Oct-3/4, and serum CA 125 as diagnostic and prognostic markers of malignant ovarian germ cell tumors. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 29 (1), 50-6 (2008) (Pubitemid 351733220)
175. L. Pegoraro, A. Palumbo, J. Erikson, M. Falda, B. Giovanazzo, B. S. Emanuel, G. Rovera, P. C. Nowell and C. M. Croce: A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proceedings of the National Academy of Sciences of the United States of America, 81 (22), 7166- 70 (1984) (Pubitemid 15216717)
176. Y. Tsujimoto, L. R. Finger, J. Yunis, P. C. Nowell and C. M. Croce: Cloning of the chromosome breakpoint of neoplastic B cells with the t (14;18) chromosome translocation. Science, 226 (4678), 1097-9 (1984)
177. S. W. Fesik and Y. Shi: Structural biology. Controlling the caspases. Science, 294 (5546), 1477-8 (2001)
178. L. M. Dejean, S. Martinez-Caballero, S. Manon and K. W. Kinnally: Regulation of the mitochondrial apoptosis-induced channel, MAC, by BCL-2 family proteins. Biochimica et biophysica acta, 1762 (2), 191-201 (2006) (Pubitemid 43006025)
179. S. K. Kassim, H. S. Ali, M. M. Sallam, S. T. Fayed, L. S. Seada, E. abd-Elkawy, M. A. Seada and A. Khalifa: Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer. Clinical biochemistry, 32 (5), 333-8 (1999) (Pubitemid 29416723)
180. Y. Mano, Y. Kikuchi, K. Yamamoto, T. Kita, J. Hirata, T. Tode, K. Ishii and I. Nagata: BCL-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. European journal of cancer, 35 (8), 1214-9 (1999) (Pubitemid 29359181)
181. P. J. Beale, P. Rogers, F. Boxall, S. Y. Sharp and L. R. Kelland: BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. British journal of cancer, 82 (2), 436-40 (2000) (Pubitemid 30045394)
182. M. R. Raspollini, G. Amunni, A. Villanucci, F. Castiglione, D. R. Degl'Innocenti, G. Baroni, M. Paglierani and G. L. Taddei: HER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival. Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry, 14 (2), 181-6 (2006) (Pubitemid 43941182)
183. F. Nezhat, C. Cohen, J. Rahaman, H. Gretz, P. Cole and T. Kalir: Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts. Cancer, 94 (11), 2935-40 (2002) (Pubitemid 34547693)
184. N. S. Anderson, L. Turner, S. Livingston, R. Chen, S. V. Nicosia and P. A. Kruk: BCL-2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation. Journal of ovarian research, 2, 16 (2009)
185. E. V. Hogdall, L. Christensen, S. K. Kjaer, J. Blaakaer, I. J. Christensen and C. K. Hogdall: Limited prognostic value of tissue protein expression levels of BCl- 2 in Danish ovarian cancer patients: from the Danish 'MALOVA' ovarian cancer study. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 118 (8), 557-64 (2010)
186. M. A. Febbraio and B. K. Pedersen: Contractioninduced myokine production and release: is skeletal muscle an endocrine organ? Exercise and sport sciences reviews, 33 (3), 114-9 (2005) (Pubitemid 40994563)
187. L. A. Hefler, C. Grimm, S. Ackermann, S. Malur, A. R. Radjabi-Rahat, S. Leodolter, M. W. Beckmann, R. Zeillinger, H. Koelbl and C. B. Tempfer: An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer research, 63 (12), 3066-8 (2003)
188. R. Garg, M. Wollan, V. Galic, R. Garcia, B. A. Goff, H. J. Gray and E. Swisher: Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecologic oncology, 103 (3), 793-6 (2006) (Pubitemid 44821354)
189. B. E. Barton: Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes. Expert opinion on therapeutic targets, 9 (4), 737-52 (2005) (Pubitemid 41131676)
190. J. S. Smolen and R. N. Maini: Interleukin-6: a new therapeutic target. Arthritis research & therapy, 8 Suppl 2, S5 (2006)
191. K. S. Rath, H. M. Funk, M. C. Bowling, W. E. Richards and A. F. Drew: Expression of soluble interleukin-6 receptor in malignant ovarian tissue. American journal of obstetrics and gynecology, 203 (3), 230 e1-8 (2010)
192. Y. Guo, J. Nemeth, C. O'Brien, M. Susa, X. Liu, Z. Zhang, E. Choy, H. Mankin, F. Hornicek and Z. Duan: Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 16 (23), 5759- 69 (2010)
193. A. Guweidhi, J. Kleeff, H. Adwan, N. A. Giese, M. N. Wente, T. Giese, M. W. Buchler, M. R. Berger and H. Friess: Osteonectin influences growth and invasion of pancreatic cancer cells. Annals of surgery, 242 (2), 224-34 (2005) (Pubitemid 41033439)
194. P. J. Paley, B. A. Goff, A. M. Gown, B. E. Greer and E. H. Sage: Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gynecologic oncology, 78 (3 Pt 1), 336-41 (2000)
195. T. J. Brown, P. A. Shaw, X. Karp, M. H. Huynh, H. Begley and M. J. Ringuette: Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecologic oncology, 75 (1), 25-33 (1999) (Pubitemid 29477797)
196. S. C. Mok, W. Y. Chan, K. K. Wong, M. G. Muto and R. S. Berkowitz: SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene, 12 (9), 1895-901 (1996) (Pubitemid 26154661)
197. G. K. Yiu, W. Y. Chan, S. W. Ng, P. S. Chan, K. K. Cheung, R. S. Berkowitz and S. C. Mok: SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. The American journal of pathology, 159 (2), 609-22 (2001) (Pubitemid 32751091)
198. N. Said and K. Motamed: Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. The American journal of pathology, 167 (6), 1739-52 (2005) (Pubitemid 41713324)
199. N. Said, I. Najwer and K. Motamed: Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. The American journal of pathology, 170 (3), 1054-63 (2007) (Pubitemid 47339372)
200. N. A. Said, I. Najwer, M. J. Socha, D. J. Fulton, S. C. Mok and K. Motamed: SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia, 9 (1), 23- 35 (2007) (Pubitemid 46203932)
201. N. A. Said, A. A. Elmarakby, J. D. Imig, D. J. Fulton and K. Motamed: SPARC ameliorates ovarian cancer-associated inflammation. Neoplasia, 10 (10), 1092-104 (2008)
202. S. L. Bull Phelps, J. Carbon, A. Miller, E. Castro- Rivera, S. Arnold, R. A. Brekken and J. S. Lea: Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. American journal of obstetrics and gynecology, 200 (2), 180 e1-7 (2009)
203. M. J. Socha, N. Said, Y. Dai, J. Kwong, P. Ramalingam, V. Trieu, N. Desai, S. C. Mok and K. Motamed: Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia, 11 (2), 126-35 (2009)
204. C. J. Robinson and S. E. Stringer: The splice variants of vascular endothelial growth factor (VEGF) and their receptors. Journal of cell science, 114 (Pt 5), 853-65 (2001) (Pubitemid 32273121)
205. P. J. Paley, K. A. Staskus, K. Gebhard, D. Mohanraj, L. B. Twiggs, L. F. Carson and S. Ramakrishnan: Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer, 80 (1), 98-106 (1997) (Pubitemid 27270925)
206. Y. Ishii: (Expression and subtype analysis of vascular endothelial growth factor (VEGF) and its receptor (flt-1) in human ovarian tumors). Nippon Sanka Fujinka Gakkai zasshi, 47 (2), 133-40 (1995)
207. Y. Nakanishi, J. Kodama, M. Yoshinouchi, K. Tokumo, S. Kamimura, H. Okuda and T. Kudo: The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 16 (3), 256-62 (1997) (Pubitemid 27282300)
208. P. G. Artini, M. Ruggiero, P. Monteleone, A. Carpi, F. Cristello, V. Cela and A. R. Genazzani: Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 62 (6), 373-7 (2008) (Pubitemid 351899098)
209. K. D. Steffensen, M. Waldstrom, I. Brandslund and A. Jakobsen: The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecologic oncology, 117 (1), 109-16 (2010)
210. A. Gadducci, P. Viacava, S. Cosio, D. Cecchetti, G. Fanelli, A. Fanucchi, G. Teti and A. R. Genazzani: Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Anticancer research, 23 (3C), 3001-8 (2003)
211. L. A. Hefler, A. Mustea, D. Konsgen, N. Concin, B. Tanner, R. Strick, G. Heinze, C. Grimm, E. Schuster, C. Tempfer, A. Reinthaller and R. Zeillinger: Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 13 (3), 898-901 (2007) (Pubitemid 46340365)
212. C. A. Boocock, D. S. Charnock-Jones, A. M. Sharkey, J. McLaren, P. J. Barker, K. A. Wright, P. R. Twentyman and S. K. Smith: Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. Journal of the National Cancer Institute, 87 (7), 506-16 (1995)
213. K. Holmes, O. L. Roberts, A. M. Thomas and M. J. Cross: Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cellular signalling, 19 (10), 2003-12 (2007) (Pubitemid 47354167)
214. G. M. Abu-Jawdeh, J. D. Faix, J. Niloff, K. Tognazzi, E. Manseau, H. F. Dvorak and L. F. Brown: Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Laboratory investigation; a journal of technical methods and pathology, 74 (6), 1105-15 (1996) (Pubitemid 26184421)
215. M. K. Oehler and H. Caffier: Diagnostic value of serum VEGF in women with ovarian tumors. Anticancer research, 19 (4A), 2519-22 (1999) (Pubitemid 29392404)
216. A. Gadducci, M. Ferdeghini, A. Fanucchi, C. Annicchiarico, B. Ciampi, C. Prontera and A. R. Genazzani: Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer research, 19 (2B), 1401-5 (1999)
217. E. M. Hartenbach, T. A. Olson, J. J. Goswitz, D. Mohanraj, L. B. Twiggs, L. F. Carson and S. Ramakrishnan: Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer letters, 121 (2), 169-75 (1997) (Pubitemid 28008916)
218. C. Tempfer, A. Obermair, L. Hefler, G. Haeusler, G. Gitsch and C. Kainz: Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstetrics and gynecology, 92 (3), 360-3 (1998) (Pubitemid 28396857)
219. B. C. Cooper, J. M. Ritchie, C. L. Broghammer, J. Coffin, J. I. Sorosky, R. E. Buller, M. J. Hendrix and A. K. Sood: Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 8 (10), 3193-7 (2002)
220. S. Yamamoto, I. Konishi, M. Mandai, H. Kuroda, T. Komatsu, K. Nanbu, H. Sakahara and T. Mori: Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. British journal of cancer, 76 (9), 1221-7 (1997)
221. G. H. Shen, M. Ghazizadeh, O. Kawanami, H. Shimizu, E. Jin, T. Araki and Y. Sugisaki: Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. British journal of cancer, 83 (2), 196-203 (2000) (Pubitemid 30411717)
222. M. K. Oehler and H. Caffier: Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer research, 20 (6D), 5109-12 (2000) (Pubitemid 32319090)
223. H. M. Tanir, S. Ozalp, O. T. Yalcin, O. Colak, A. Akcay and T. Senses: Preoperative serum vascular endothelial growth factor (VEGF) in ovarian masses. European journal of gynaecological oncology, 24 (3-4), 271-4 (2003) (Pubitemid 36644614)
224. S. K. Kassim, E. M. El-Salahy, S. T. Fayed, S. A. Helal, T. Helal, D. Azzam Eel and A. Khalifa: Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clinical biochemistry, 37 (5), 363-9 (2004) (Pubitemid 38490454)
225. L. Li, L. Wang, W. Zhang, B. Tang, J. Zhang, H. Song, D. Yao, Y. Tang, X. Chen, Z. Yang, G. Wang, X. Li, J. Zhao, H. Ding, E. Reed and Q. Q. Li: Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer research, 24 (3b), 1973-9 (2004)
226. C. Rudlowski, A. K. Pickart, C. Fuhljahn, T. Friepoertner, B. Schlehe, S. Biesterfeld and W. Schroeder: Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 16 Suppl 1, 183-9 (2006)
227. D. O. Bates and S. J. Harper: Therapeutic potential of inhibitory VEGF splice variants. Future oncology, 1 (4), 467-73 (2005)
228. Y. Bai, H. Deng, Y. Yang, X. Zhao, Y. Wei, G. Xie, Z. Li, X. Chen, L. Chen, Y. Wang, D. Su, Z. Qian, Q. Zhong, H. Luo and T. Yi: VEGF-targeted short hairpin RNA inhibits intraperitoneal ovarian cancer growth in nude mice. Oncology, 77 (6), 385-94 (2009)
229. S. A. Adham, I. Sher and B. L. Coomber: Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells. Laboratory investigation; a journal of technical methods and pathology, 90 (5), 709-23 (2010)
230. E. S. Han and B. J. Monk: Bevacizumab in the treatment of ovarian cancer. Expert review of anticancer therapy, 7 (10), 1339-45 (2007) (Pubitemid 351826900)
231. S. Mabuchi, C. Kawase, D. A. Altomare, K. Morishige, M. Hayashi, K. Sawada, K. Ito, Y. Terai, Y. Nishio, A. J. Klein-Szanto, R. A. Burger, M. Ohmichi, J. R. Testa and T. Kimura: Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Molecular cancer therapeutics, 9 (8), 2411-22 (2010)